<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7120516/results/search/test_trace/results.xml">
  <result pre="of genetic makeup in development and progression of diseases and" exact="treatment" post="in various viral diseases. Current and previous decade have"/>
  <result pre="helping us to understand the complex interactions involved in the" exact="infection" post="process. The pharmaceutical industry is exploiting this information to"/>
  <result pre="annually (Viral Hepatitis Prevention Board 1997). Hepatitis B virus (HBV)" exact="infection" post="is a serious global health problem, with 2 billion"/>
  <result pre="Report.3 1997; WHO fact sheet 2000). Hepatitis B virus (HBV)" exact="infection" post="is a major global public health problem. Of the"/>
  <result pre="develop cirrhosis, liver failure, or hepatocellular carcinoma (Lok 2002). HBV" exact="infection" post="accounts for 500,000–1.2 million deaths each year (Mahoney 1999;"/>
  <result pre="liver disease worldwide. The most recent WHO estimate of the" exact="prevalence" post="of HCV infection is 2 %, representing 123 million"/>
  <result pre="The most recent WHO estimate of the prevalence of HCV" exact="infection" post="is 2 %, representing 123 million people (Perz et"/>
  <result pre="transplantation in developed countries and the most common chronic blood-borne" exact="infection" post="in the USA. There is a wide range of"/>
  <result pre="infection in the USA. There is a wide range of" exact="prevalence" post="estimates among developing countries and generally less data available"/>
  <result pre="of disease than in the developed world. This range in" exact="prevalence" post="is reflected in reviewing the estimates from developing countries"/>
  <result pre="% (Chowdhury et al. 2003). Countries with the highest reported" exact="prevalence" post="rates are located in Africa and Asia; areas with"/>
  <result pre="rates are located in Africa and Asia; areas with lower" exact="prevalence" post="include the industrialized nations in North America, Northern and"/>
  <result pre="of cervical cancer deaths are around 250,000 per year. The" exact="prevalence" post="of genital HPV infection in the world is around"/>
  <result pre="are around 250,000 per year. The prevalence of genital HPV" exact="infection" post="in the world is around 440 million. There are"/>
  <result pre="of which occur in developing countries, where neither population-based routine" exact="screening" post="(e.g., Papanicolaou smear test) nor optimal treatment is available."/>
  <result pre="neither population-based routine screening (e.g., Papanicolaou smear test) nor optimal" exact="treatment" post="is available. The highest estimated incidence rates of cervical"/>
  <result pre="lifetime, 60 % with transient infection, 10 % with persistent" exact="infection" post="(confirmed by detection of HPV DNA in genital samples),"/>
  <result pre="with transient infection, 10 % with persistent infection (confirmed by" exact="detection" post="of HPV DNA in genital samples), 4 % with"/>
  <result pre="year and 90 % in 2 years. However, when the" exact="infection" post="persists – in 5–10 % of infected women –"/>
  <result pre="This process usually takes 10–15 years, providing many opportunities for" exact="detection" post="and treatment of the precancerous lesion. Progression to invasive"/>
  <result pre="usually takes 10–15 years, providing many opportunities for detection and" exact="treatment" post="of the precancerous lesion. Progression to invasive cancer can"/>
  <result pre="cases involve loss of fertility. In more developed countries, cervical" exact="screening" post="using a Papanicolaou (Pap) test or liquid-based cytology is"/>
  <result pre="than 500,000 in 1918. Seasonal influenza is an acute viral" exact="infection" post="caused by an influenza virus. There are three types"/>
  <result pre="transmit from person to person. Almost all people with H5N1" exact="infection" post="have had close contact with infected birds or H5N1-contaminated"/>
  <result pre="person. Almost all people with H5N1 infection have had close" exact="contact" post="with infected birds or H5N1-contaminated environments. When people do"/>
  <result pre="in humans. However, some countries have reported cases of human" exact="infection" post="with SIVs. Most of these human infections have been"/>
  <result pre="(over half of these drugs are being used in the" exact="treatment" post="of patients with HIV infection), while there is no"/>
  <result pre="treatment of patients with HIV infection), while there is no" exact="treatment" post="for most acute infections, such as the ones that"/>
  <result pre="variations among HIV-1 clades. HIV-1 is capable of establishing latent" exact="infection" post="in the early phases of infection (Mehandru et al."/>
  <result pre="capable of establishing latent infection in the early phases of" exact="infection" post="(Mehandru et al. 2004). HIV-1 can also escape from"/>
  <result pre="vector-specific CD4+ T cells in an increasing susceptibility to HIV" exact="infection" post="(Hutnick et al. 2010). The mechanism of T-cell exhaustion"/>
  <result pre="other clades (Van Gils et al. 2010). HIV-1 clade C" exact="infection" post="was most prevalent among elite neutralizers (Simek et al."/>
  <result pre="Env epitopes as HIV-1 vaccine candidates for bNAb generation. Natural" exact="infection" post="with HIV does not result in virus clearance by"/>
  <result pre="responses raised by monomeric gp120 vaccines in protection against HIV" exact="infection" post="has been proven beyond any doubt in the world’s"/>
  <result pre="passively to nonhuman primates can provide protection against experimental SHIV" exact="infection" post="(Ferrantelli et al. 2002). However, contrary to laboratory-adapted virus"/>
  <result pre="on the possibility for a vaccine to elicit protection against" exact="infection" post="by the induction of neutralizing antibodies alone. In view"/>
  <result pre="infections. Drug resistance is also a major obstacle in the" exact="treatment" post="of hepatitis C virus (HCV). The essential HCV NS3/4A"/>
  <result pre="the major obstacles in their clinical application in treating HBV" exact="infection" post="(Lau et al. 1997; Hoofnagle and di Bisceglie 1997)."/>
  <result pre="inhibiting HBV replication. Antiretroviral Resistance Assays The purpose of resistance" exact="testing" post="is to make available the information to assist in"/>
  <result pre="All guidelines come to the result that HIV drug resistance" exact="testing" post="should be performed when a HIV-infected person enters into"/>
  <result pre="maximum as possible. In HIV-infected individuals receiving antiretroviral therapy, resistance" exact="testing" post="should be performed in the presence of virological failure."/>
  <result pre="at the time of testing, although guidelines agree that resistance" exact="testing" post="could be also attempted in individuals with HIV-1 RNA"/>
  <result pre="chances of amplifying HIV-1 sequences are markedly lower. Drug resistance" exact="testing" post="might also be helpful when managing suboptimal viral load"/>
  <result pre="viral suppression. Importantly, given that drug resistance mutations wane after" exact="treatment" post="interruption, drug resistance testing in the setting of virological"/>
  <result pre="that drug resistance mutations wane after treatment interruption, drug resistance" exact="testing" post="in the setting of virological failure should be performed"/>
  <result pre="and D’Aquila 2001; Hirsch et al. 2008). But these two" exact="tests" post="are also not up to mark as not useful"/>
  <result pre="predicting short-term virologic outcome Unclear relevance of certain mutations Allow" exact="detection" post="of emerging mutations before onset of resistance Drug resistance"/>
  <result pre="interaction between drugs in combination therapy Straightforward interpretation Highly complex" exact="testing" post="platform with longer turnaround time Increased cost Virtual phenotype"/>
  <result pre="entire nucleotide sequence Showed good correlation for most drugs These" exact="tests" post="have limited sensitivity for the detection of minority variants"/>
  <result pre="for most drugs These tests have limited sensitivity for the" exact="detection" post="of minority variants in the viral population, so detection"/>
  <result pre="the detection of minority variants in the viral population, so" exact="detection" post="of non-B subtypes may be limited for some tests,"/>
  <result pre="al. 2008). Table 28.2 shows the recent advances in resistances" exact="testing" post="at minority levels. Table 28.2 The recent advances in"/>
  <result pre="at minority levels. Table 28.2 The recent advances in resistances" exact="testing" post="at minority levels Allele-specific PCR Single genome sequencing Ultra-deep"/>
  <result pre="Sensitivity, positive predictive value, and negative predictive value Linkage mutation" exact="detection" post="Linkage, sensitivity, accuracy, negative predictive value, rapidity of results"/>
  <result pre="concept of medicine, i.e., well-known as personalized medicine concept where" exact="treatment" post="will be based on individuals’ genome composition as well"/>
  <result pre="against the fatal viral diseases, so more effective personalized clinical" exact="treatment" post="strategies may be developed. Personalized Medicine: Promising a Solution"/>
  <result pre="fluctuate even on a daily basis. The variances between repeated" exact="tests" post="using the same kit are usually smaller than those"/>
  <result pre="et al. 2007). Firstly, it currently serves as a complementary" exact="diagnosis" post="of HIV infection and may become one of the"/>
  <result pre="Firstly, it currently serves as a complementary diagnosis of HIV" exact="infection" post="and may become one of the diagnosis standards in"/>
  <result pre="diagnosis of HIV infection and may become one of the" exact="diagnosis" post="standards in the near future. For qualitative determination of"/>
  <result pre="the viral load value is measured, the more confident a" exact="diagnosis" post="of HIV infection can be drawn. For example, if"/>
  <result pre="value is measured, the more confident a diagnosis of HIV" exact="infection" post="can be drawn. For example, if the viral load"/>
  <result pre="load is higher than 3,000 copies/ml, the probability of HIV" exact="infection" post="of the individual from whom the sample is taken"/>
  <result pre="a different time. Secondly, viral load is helpful for early" exact="diagnosis" post="of HIV infection. It is reported that there is"/>
  <result pre="viral load assay can also be used in the complementary" exact="diagnosis" post="of HIV infection for neonates from HIV-infected mothers. Although"/>
  <result pre="can also be used in the complementary diagnosis of HIV" exact="infection" post="for neonates from HIV-infected mothers. Although the antibody-based HIV"/>
  <result pre="from HIV-infected mothers. Although the antibody-based HIV assay is the" exact="diagnosis" post="standard in clinical practice, it is useless during its"/>
  <result pre="useless during its window period in the early stage of" exact="infection" post="and has no diagnostic value for infants from HIV-infected"/>
  <result pre="al. 2007). Patients with higher CD4+ T-cell counts following the" exact="treatment" post="appeared to have survived after month 3, whereas those"/>
  <result pre="factor for choosing the PCR-based, hybridization-based, or isothermal amplification-based HIV" exact="detection" post="assays. Polymerase chain reaction (PCR)- or rt-PCR-based assay is"/>
  <result pre="PCR and rt-PCR are used as qualitative assays of viral" exact="infection" post="targeting the integrated form of provirus or the free"/>
  <result pre="an understanding of these relations to devise novel personalized pharmacological" exact="treatment" post="strategies that maximize the potential for therapeutic benefit and"/>
  <result pre="rare variants to drug sensitivity (Ramsey et al. 2012). Genetic" exact="screening" post="of HIV for prediction of resistance is recommended by"/>
  <result pre="therapy or after failure of an initial regimen. Genotypic resistance" exact="testing" post="has been judged to be cost-effective, even with the"/>
  <result pre="cost-effective, even with the relatively high current costs of the" exact="tests" post="(Weinstein et al. 2001). At present, the majority of"/>
  <result pre="et al. 2001). At present, the majority of genetic resistance" exact="testing" post="for HIV drugs involves sequence-based approaches; however, kit-based tests"/>
  <result pre="resistance testing for HIV drugs involves sequence-based approaches; however, kit-based" exact="tests" post="are expected to become common and testing costs should"/>
  <result pre="approaches; however, kit-based tests are expected to become common and" exact="testing" post="costs should fall automatically. These tests are also likely"/>
  <result pre="to become common and testing costs should fall automatically. These" exact="tests" post="are also likely to expand beyond the viral genome,"/>
  <result pre="additional polymorphisms in the host genome are linked to HIV" exact="treatment" post="outcome. Before exploring the applications of pharmacogenomics on HIV,"/>
  <result pre="In fact, some major innovations have already occurred in resistance" exact="testing" post="technologies and in HIV treatment selection based on genomics."/>
  <result pre="have already occurred in resistance testing technologies and in HIV" exact="treatment" post="selection based on genomics. Genotyping and phenotyping are two"/>
  <result pre="the source of the sequence sample and the antiretroviral drug" exact="treatment" post="history of the individual from whom the isolate was"/>
  <result pre="thus effectively reduces viral burden in chronic HBV carriers. Long-term" exact="treatment" post="with lamivudine may, however, lead to resistance as the"/>
  <result pre="and combinations of antiretroviral drugs. Prediction of Drug Toxicity SNP" exact="detection" post="has been used to predict adverse events in antiretroviral"/>
  <result pre="recently emerged in a variety of clinical settings. Genotype resistance" exact="testing" post="of HIV isolates has demonstrable clinical use and provides"/>
  <result pre="are rising (Klein et al. 2009). Moreover, HIV viral load" exact="testing" post="has served as the major guide to the selection"/>
  <result pre="to gene mutations and SNPs as well as provide rapid" exact="screening" post="information regarding mRNA expression. Transcriptional profiling has the ability"/>
  <result pre="carcinogenesis and are thought to influence who develops persistent HPV" exact="infection" post="and perhaps who further progresses to cancer (Czene et"/>
  <result pre="disease has been extensively studied. From its initiation through HPV" exact="infection" post="at the cervical transformation zone, and subsequent steps related"/>
  <result pre="antiviral responses and thus are associated with disease progression and" exact="treatment" post="response. Table 28.7 The susceptibility of various genotypes in"/>
  <result pre="Organ or system involved phenotype Associated gene/allele Drug/drug response HIV-1" exact="infection" post="CCR5 Maraviroc efficacy Hepatitis C infection IL28B Interferon-alpha efficacy"/>
  <result pre="gene/allele Drug/drug response HIV-1 infection CCR5 Maraviroc efficacy Hepatitis C" exact="infection" post="IL28B Interferon-alpha efficacy Type III Interferon-Based Therapy As presented"/>
  <result pre="role of the IL28B gene in the pathogenesis of HCV" exact="infection" post="(Ge et al. 2009; Suppiah et al. 2009). However,"/>
  <result pre="at the major portals of entry into the body before" exact="infection" post="is established, without activating other arms of the immune"/>
  <result pre="recovery, they do not explain why treatment-associated resolution of HCV" exact="infection" post="is associated with certain base sequences located upstream of"/>
  <result pre="as a predictor of outcome in patients treated for HCV" exact="infection" post="will have major practical implications. Several recent GWAS studies"/>
  <result pre="initiate treatment. These findings may also lead to more individualized" exact="treatment" post="regimens with regard to both the chosen medicines and"/>
  <result pre="Welzel and colleagues investigated the association between genetics and HCV" exact="treatment" post="response with a focus on the IFN-alpha pathway (Welzel"/>
  <result pre="with fibrosis score 3 had not previously responded to IFN" exact="treatment" post="with or without RBV, had a Child–Turcotte–Pugh score of"/>
  <result pre="logistic regression with feature selection to predict IFN-alpha and RBV" exact="treatment" post="outcomes using genetic factors. The cohort of 523 CHC"/>
  <result pre="of these trials may not detect toxicities with a low" exact="prevalence" post="rate; Table 28.11 shows the adverse effects associated with"/>
  <result pre="responsiveness to tenofovir M184V Observed in most viruses resistant to" exact="treatment" post="with lamivudine Confers high-level resistance to lamivudine in vitro"/>
  <result pre="AIDS Society-USA 2002) Table 28.13 Antiretroviral agents used in the" exact="treatment" post="of HIV infection Drugs Mechanisms of action Mechanisms of"/>
  <result pre="Table 28.13 Antiretroviral agents used in the treatment of HIV" exact="infection" post="Drugs Mechanisms of action Mechanisms of resistance Nucleoside analogues"/>
  <result pre="The mutations that are selected for after the failure of" exact="treatment" post="with nonnucleoside reverse transcriptase inhibitors are all located in"/>
  <result pre="modify the number and the nature of the points of" exact="contact" post="between the inhibitors and the protease, thereby reducing their"/>
  <result pre="the HIV protease and reverse transcriptase sufficient to produce patent" exact="treatment" post="failure, resistance may not have reached maximal levels, and"/>
  <result pre="can occur even in the absence of any changes in" exact="treatment" post="(Barbour et al. 2002). Indeed, the development of complete"/>
  <result pre="face of resistance mutations. Such knowledge may help in the" exact="treatment" post="of patients infected with viruses that express resistance to"/>
  <result pre="resistant viruses have lost some of their virulence. When antiretroviral" exact="treatment" post="is interrupted in patients infected with HIV that is"/>
  <result pre="the baseline nucleotide sequences among 11 subjects with primary HIV" exact="infection" post="who showed variation against antiretroviral therapy (Little et al."/>
  <result pre="samples were collected for a median of 225 days after" exact="infection" post="and analyzed for persistence of transmitted drug-resistant variants. Seven"/>
  <result pre="with resistance to NNRTIs. There were no differences in the" exact="prevalence" post="or type of mutations between the groups. For subjects"/>
  <result pre="of 260 cells/mm3. Because of a glaringly high number of" exact="treatment" post="failures being documented in the triple-NRTI group, the study"/>
  <result pre="phenomenon can be found in a clinical trial of partial" exact="treatment" post="interruptions conducted by Dr. Steven Deeks and his colleagues"/>
  <result pre="cohort of HIV-positive individuals who had a history of excellent" exact="treatment" post="adherence, had drug-resistant viremia (greater than 400 copies/ml), and"/>
  <result pre="lamivudine in four highly treatment-experienced patients with no viable alternative" exact="treatment" post="options and evidence of the M184V mutation while on"/>
  <result pre="60 and 100 %, respectively. The used of a genetic" exact="tests" post="for HLA-B5701 led to a reduction in ABC-related HSR"/>
  <result pre="is the first example of a clinical use of genetic" exact="screening" post="in HIV disease management to get widespread approval. Other"/>
  <result pre="have undergone a range of treatments. If the molecular diagnostic" exact="tests" post="can be made less expensive, it will make able"/>
  <result pre="imputation: selective serotonin reuptake inhibitor response pharmacogenomicsPharmacogenet Genomics20122224725322322242 AlterMJKruszon-MoranDNainanOVet al.The" exact="prevalence" post="of hepatitis C virus infection in the United States,"/>
  <result pre="response pharmacogenomicsPharmacogenet Genomics20122224725322322242 AlterMJKruszon-MoranDNainanOVet al.The prevalence of hepatitis C virus" exact="infection" post="in the United States, 1988 through 1994N Engl J"/>
  <result pre="immunodeficiency virus type 1J Virol2001753291330011238855 Blum RA (2005) HIV resistance" exact="testing" post="in the USA – a model for the application"/>
  <result pre="substrate envelope hypothesisChem Biol Drug Des200769529831317539822 ChowdhuryASantraAChaudhuriSet al.Hepatitis C virus" exact="infection" post="in the general population: a community-based study in West"/>
  <result pre="C treatment-induced viral clearanceNature200946139940119684573 GirardMMeignierBBarre-SinoussiFet al.Vaccine-induced protection of chimpanzees against" exact="infection" post="by a heterologous human immunodeficiency virus type 1J Virol19956910623962487666524"/>
  <result pre="side effectsAIDS2004182391240015622315 HannaGJD’AquilaRTClinical use of genotypic and phenotypic drug resistance" exact="testing" post="to monitor antiretroviral chemotherapyClin Infect Dis20013277478211229846 HannaGJJohnsonVAKuritzkesDRet al.Patterns of"/>
  <result pre="chemotherapyClin Infect Dis20013277478211229846 HannaGJJohnsonVAKuritzkesDRet al.Patterns of resistance mutations selected by" exact="treatment" post="of human immunodeficiency virus type 1 infection with zidovudine,"/>
  <result pre="mutations selected by treatment of human immunodeficiency virus type 1" exact="infection" post="with zidovudine, didanosine, and nevirapineJ Infect Dis200018190491110720511 HarroCet al.Safety"/>
  <result pre="in healthy adultsClin Vaccine Immunol2009161285129219605598 HavlirDVHellmannNSPetropoulosCJet al.Drug susceptibility in HIV" exact="infection" post="after viral rebound in patients receiving indinavir-containing regimensJAMA200028322923410634339 HemminkiKChenBFamilial"/>
  <result pre="of cervical cancer: a reviewVirus Res20028922924012445662 HirschMSet al.Antiretroviral drug resistance" exact="testing" post="in adult HIV-1 infection: recommendations of an International AIDS"/>
  <result pre="AIDS Society-USA panelJ Am Med Assoc200028324172426 HirschMSGünthardHFSchapiroJMet al.Antiretroviral drug resistance" exact="testing" post="in adult HIV-1 infection: 2008 recommendations of an International"/>
  <result pre="insights into the mechanisms of drug resistanceProtein Sci200091898190411106162 HoofnagleJHdi BisceglieAMThe" exact="treatment" post="of chronic viral hepatitisN Engl J Med199733653473569011789 HsiouYDingJDasKet al.The"/>
  <result pre="KingJKYehSHLinMWet al.Genetic polymorphisms in interferon pathway and response to interferon" exact="treatment" post="in hepatitis B patients: a pilot studyHepatology2002361416142412447867 KleinTEet al.Estimation"/>
  <result pre="Persistence of transmitted drug-resistant virus among patients with primary HIV" exact="infection" post="deferring antiretroviral therapy [Abstract 36LB]. In: 11th conference on"/>
  <result pre="immunity following antiretroviral treatmentJ Clin Invest200110750551711181650 MallalSPhillipsECarosiGWorkmanCPREDICT-1 Study Team. HLA-B*5701" exact="screening" post="for hypersensitivity to abacavirN Engl J Med200835856865718256392 MammanoFPetitCClavelFResistance-associated loss"/>
  <result pre="al.Interferon alfa-2b alone or in combination with ribavirin as initial" exact="treatment" post="for chronic hepatitis C. Hepatitis Interventional Therapy GroupN Engl"/>
  <result pre="Rev Immunol20022428329112001999 McMichaelAJRowland-JonesSLCellular immune responses to HIVNature200141098098711309628 MehandruSet al.Primary HIV-1" exact="infection" post="is associated with preferential depletion of CD4+ T lymphocytes"/>
  <result pre="Microbiol2000384034404111060065 NalamMNSchifferCANew approaches to HIV protease inhibitor drug design II:" exact="testing" post="the substrate envelope hypothesis to avoid drug resistance and"/>
  <result pre="during suboptimal therapyAIDS1999132349235910597776 OhshimaSKomatsuMNakaneKet al.Iatrogenic GB virus C/hepatitis G virus" exact="infection" post="in an area endemic for hepatitis C virusJ Hosp"/>
  <result pre="LA, Pecoraro C, Hutin YJF, Armstrong GL (2004) Estimated global" exact="prevalence" post="of hepatitis C virus infection. In: 42nd annual meeting"/>
  <result pre="variation in IL28B is associated with chronic hepatitis C and" exact="treatment" post="failure: a genomewide association studyGastroenterology20101381338134520060832 ReevesJDGalloSAAhmadNet al.Sensitivity of HIV-1"/>
  <result pre="(2007) http://data.unaids.org/pub/EPISlides/2007/071118_epi_regional%20factsheet_en.pdf Rerks-NgarmSPitisuttithumPNitayaphanSVaccination with ALVAC and AIDSVAX to prevent HIV-1" exact="infection" post="in ThailandN Engl J Med20093612209222019843557 RichmanDDSusceptibility to nucleoside analogues"/>
  <result pre="potent neutralizing activity identified by using a high through put" exact="neutralization assay" post="together with an analytical selection algorithmJ Virol2009837337734819439467 SquiresKYoungBPatelPet al.First"/>
  <result pre="Virol2009837337734819439467 SquiresKYoungBPatelPet al.First large, multicenter, open label study utilizing HLA-B*5701" exact="screening" post="for abacavir hypersensitivity in North AmericaAIDS2008221673167518670229 StevensWHorsfieldPScottLEEvaluation of the"/>
  <result pre="typing technologies for pharmacogenomicsCurr Top Med Chem20044131423143115379655 Van GilsMJet al.High" exact="prevalence" post="of neutralizing activity against multiple unrelated human immunodeficiency virus"/>
  <result pre="6. http://hgins.uia.ac.be/esoc/VHPB/maltatxt.html WedemeyerHSchullerESchlaphoffVStauberREWiegandJSchiefkeIFirbasCJilmaBThurszMZeuzemSHofmannWPHinrichsenHTauberEMannsMPKladeCSTherapeutic vaccine IC41 as late add-on to standard" exact="treatment" post="in patients with chronic hepatitis CVaccine200927375142515119559112 WeiXDeckerJMWangSet al.Antibody neutralization"/>
  <result pre="methyltransferase activityAm J Hum Genet1980326516627191632 WeinsteinCet al.Use of genotypic resistance" exact="testing" post="to guide hiv therapy: clinical impact and cost-effectivenessAnn Intern"/>
  <result pre="pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for" exact="treatment" post="of chronic hepatitis C virus infection in the hepatitis"/>
  <result pre="interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus" exact="infection" post="in the hepatitis C antiviral long-term treatment against cirrhosis"/>
  <result pre="hepatitis C virus infection in the hepatitis C antiviral long-term" exact="treatment" post="against cirrhosis trialHepatology20094961847185819434718 World Health Organization (1997) The world"/>
 </snippets>
</snippetsTree>
